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Open access under CC BYBackground: Human papillomavirus (HPV) is a cause of oropharyngeal cancer, but a role for HPV in the
etiology of oral cavity squamous cell carcinomas (OCSCC) remains uncertain.
Methods: We sought to estimate the etiologic fraction for HPV among consecutive, incident OCSCC diag-
nosed from 2005 to 2011 at four North American hospitals. DNA and RNA puriﬁed from parafﬁn-embed-
ded tumors were considered evaluable if positive for DNA and mRNA control genes by quantitative PCR.
Fifteen high-risk (HR) HPV types were detected in tumors by consensus PCR followed by type-speciﬁc
HR-HPV E6/7 oncogene expression by quantitative reverse-transcriptase PCR. P16 expression was evalu-
ated by immunohistochemistry (IHC). A study of 400 cases allowed for precision to estimate an etiologic
fraction of as low as 0% (97.5% conﬁdence interval, 0–0.92%).
Results: Of 409 evaluable OCSCC, 24 (5.9%, 95%CI 3.6–8.2) were HR-HPV E6/7 expression positive; 3.7%
(95%CI 1.8–5.5) for HPV16 and 2.2% (95%CI 0.8–3.6) for other HR-HPV types. HPV-positive tumors arose
from throughout the oral cavity (ﬂoor of mouth [n = 9], anterior tongue [6], alveolar process [4], hard pal-
ate [3], gingiva [1] and lip [1]) and were signiﬁcantly associated with male gender, small tumor stage,
poor tumor differentiation, and basaloid histopathology. P16 IHC had very good-to-excellent sensitivity
(79.2%, 95%CI 57.9–92.9), speciﬁcity (93.0%, 95%CI 90.0–95.3), and negative-predictive value (98.6%,
95%CI 96.8–99.6), but poor positive-predictive value (41.3%, 95%CI 27.0–56.8) for HR-HPV E6/7 expres-
sion in OCSCC.
Conclusion: The etiologic fraction for HR-HPV in OCSCC was 5.9%. p16 IHC had poor positive predictive
value for detection of HPV in these cancers.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. Introduction
Human papillomavirus (HPV) infection is the principal cause of
a subset of oropharyngeal squamous cell carcinomas (OPSCC). Epi-
demiological associations with sexual behavior and HPV exposure
are strong and consistent for OPSCC, but less so for oral cavity
squamous cell carcinoma (OCSCC).1 A role for HPV in the pathogen-
esis of OCSCC therefore remains somewhat controversial.
In a systematic review by Kreimer and colleagues, HPV DNA
was detected in 24% of OCSCC worldwide.2 However, the presence
of HPV DNA alone is insufﬁcient evidence for a causal association
from a molecular perspective. Expression of HPV oncogenes E6venue, Room 620, Columbus,
+1 614 688 4245.
illison).
-NC-ND license. and E7 remains a gold standard for classiﬁcation of an HPV-caused
cancer and is necessary for tumor initiation3 and maintenance of
the malignant phenotype4,5 in model systems of oral cancer. While
case reports have provided compelling evidence of HPV E6/E7
expression in some cases of OCSCC5,6, comprehensive analyses of
large series have not been reported.
A recent analysis of OPSCC collected as part of the Surveillance,
Epidemiology and End Results (SEERs) program in the United
States (US) estimated that the proportion of OPSCC attributable
to HPV infection increased from 16% to 72% between 1988 and
2004.7 An analogous fourfold increase in the HPV-attributable frac-
tion for OCSCC could elevate even a negligible fraction to a signif-
icant fraction at the population level. We therefore evaluated a
large series of consecutive cases of OCSCC diagnosed in North
America from 2005 to 2011 for high-risk (HR)-HPV E6/E7 oncogene
expression.
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Study population and design
A four-institution, retrospective case-series was designed to
estimate the etiologic fraction for HPV in OCSCC and was powered
to detect a prevalence of as low as 0% with precision. Zero positives
among 400 cases would provide a one-sided 97.5%CI of 0–0.92%.
Adjusted for an estimated 7.5% in-evaluable samples, a total of
430 cases were included in the analysis.
Eligible tumor specimens included consecutive, newly diag-
nosed cases of formalin-ﬁxed, parafﬁn-embedded, pathologically-
conﬁrmed, in situ or invasive squamous cell carcinoma of the oral
cavity (inclusive of lip, ventibule of mouth, gingiva, alveolar pro-
cess, tongue, buccal mucosa, hard palate, ﬂoor of mouth and retro-
molar trigone) diagnosed at four academic medical centers in
North America, including: The Ohio State University, Columbus,
OH; Princess Margaret Hospital, Toronto, CA; University of Chicago,
Chicago, IL; and The University of California, San Francisco (UCSF),
CA. Consecutive cases were identiﬁed from pathology archives ret-
rospective from a diagnosis on December 31, 2011 until a total of
430 were obtained. Anatomic site of tumor origin was determined
by the operating physician and conﬁrmed by the pathologist. Sub-
ject age, gender and AJCC TNM stage were extracted from pathol-
ogy reports, but stage was not available for some cases from a
biopsy referral service at UCSF. Institutional Review Board ap-
proval was obtained from all participating sites.Histopathological analysis
Histopathological interpretation was performed by pathologists
(AS, ML) masked to laboratory analysis. Hematoxylin and eosin
stained slides were used to conﬁrm presence and estimate the pro-
portion of in situ or invasive squamous cell carcinoma in the spec-
imen as well as to classify histopathological features, including
differentiation status (well, moderate, poor) and histopathological
variants of squamous cell carcinoma. Tumors were categorized
into variants of squamous cell carcinoma based upon the presence
of speciﬁc histopathological features as previously described for
acantholytic8,9, adenosquamous9, basaloid8,10, carcinoma cunicula-
tum11,12, verrucous carcinoma8,13, papillary8,9, spindle cell8,10,12,
and lymphoepithelial-like variants8,9.
All tumors were evaluated for expression of a surrogate bio-
marker of HPV E7 oncoprotein function, the cdk inhibitor p16, by
means of an immunohistochemical analysis with a mouse mono-
clonal antibody (MTM Laboratories, City State) visualized with
use of an autostainer and a cone-view secondary detection kit14.
Positive p16 expression was deﬁned as an H score of 60 or greater
as previously described15, where the H score was derived from the
cross product of intensity of staining (0, 1, 2, 3+) and percent of tu-
mor staining at maximum intensity.
The speciﬁcity of HPV to tumor cell nuclei was evaluated for all
tumors positive for HPV DNA by use of the in situ hybridization-
catalyzed signal ampliﬁcation method for biotinylated probe (Gen-
point, Dako, Carpinteria, CA.)16 with either a biotinylated DNA
probe that was speciﬁc for HPV16 (code Y1407, Dako) or a wide
spectrum probe for detection of HPV types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68 (code Y1443, Dako). Tumors with punctu-
ate or diffuse staining speciﬁc to tumor cell nuclei were considered
positive.Laboratory analysis
A study-speciﬁc standard operating procedure was used by all
sites for serial sectioning of parafﬁn embedded tumor blocks.New blades were used for each tumor sample. Sectioning included:
hematoxylin and eosin veriﬁcation of tumor in the specimen;
10 lm section parafﬁn curls  two for DNA and RNA isolation;
and 4 lm sections  10 mounted on adherent slides.
DNA was isolated from parafﬁn curls by use of proteinase K
digestion, phenol–chloroform extraction and ethanol
precipitation.17
Total RNA was extracted using High Pure RNA Parafﬁn Kits
(Roche, Mannheim, Germany) per the manufacturer’s protocol.
DNA and RNA quantity and purity (calculated by use of the ratio
of the absorbance at 260 nm to that at 280 nm [260/280 ratio])
were measured with the Nanodrop 2000 spectrophotometer (Ther-
mo Fisher Scientiﬁc, Inc, Wilmington, DE).
After DNase treatment, 0.3 lg of total RNA was reverse tran-
scribed to cDNA by use of High Capacity RNA-to-cDNA Master
Mix per the manufacturer’s protocol (Applied Biosystems, Carls-
bad, California). Controls with no reverse transcriptase were per-
formed in parallel for each sample.
Specimens were classiﬁed as evaluable or in-evaluable for DNA
analysis by use of a real-time Taq-Man PCR assay that ampliﬁed a
58 bp region of a control gene (human endogenous retrovirus-3,
ERV-3) as previously described.18 Brieﬂy, 2 lL of puriﬁed tumor
tissue DNAwas analyzed. A standard curve was generated in dupli-
cate from a ﬁvefold dilution series (from 150,000 to 1.92 cells) of a
diploid human cell line, CCD-18LU (ATCC, Manassas, VA). Samples
with ERV-3 values above the lower limit of reproducibility of the
assays (>3 copies) were considered evaluable.
Specimens were classiﬁed as evaluable for RNA analysis (after
reverse transcription to cDNA) by use of a real-time quantitative
Taq-Man reverse transcriptase (qRT)-PCR assay designed to ampli-
fy a 73 bp region of a housekeeping gene, human ribosomal protein
large P0 (RPLPO) as previously described.18 Samples with RPLPO
values above the lower limit of reproducibility of the assays (>3
copies) were considered evaluable.
Puriﬁed tumor DNA was evaluated for the presence of DNA of
15 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
68, 73 and 82), three potentially high-risk types (26, 53, 66)
and seven low-risk types (6, 11, 40, 43, 44, 54, 69, 71, 70, 74)
by consensus primer PCR ampliﬁcation by use of the SPF10 pri-
mer system designed to amplify a 65 bp fragment of the con-
served L1 region of the genome, followed by reverse line blot
hybridization for HPV type speciﬁcation (The Inno-LiPA assay,
Innogenetics, Gent, Belgium). Samples positive for H(human)DNA
control were considered evaluable as indicated by the
manufacturer.
HPV type-speciﬁc TaqMan quantitative real-time PCR assays
designed to amplify a 60–136 bp fragment of the E6 or E7 region
(depending on type) of the 15 HPV types classiﬁed as high-risk
as per Munoz and colleagues19 noted above were used: (1) to ana-
lyze all tumors for HPV16 E6 DNA; (2) to conﬁrm HPV type-speciﬁc
detection in samples positive by the Inno-LiPA assay; and (3) to
analyze samples in-evaluable by Inno-LiPA (human DNA control
negative) but evaluable by ERV3 for 15 HR-HPV DNA types as pre-
viously described.7,15,18 Primer and probe sequences as well as
reaction conditions are shown in Supplementary Table 1. Samples
above the lower limit of reproducibility of the assays (for all, P3
copies) were considered positive. HPV viral load in tumors was
estimated from the quotient of viral load and ERV-3, adjusted to
the percent tumor present in the sample.
Puriﬁed tumor RNA was evaluated for HR-HPV E6/7 mRNA
expression after reverse transcription to cDNA by use of HPV
type-speciﬁc quantitative real-time TaqMan PCR assays noted
above. All tumors were evaluated for HPV16 E6/7 expression. Addi-
tionally, all tumors positive for HPV DNA were evaluated for HPV
E6/7 expression by qRT-PCR for the corresponding HPV type(s) de-
tected. Results were reported as HPV E6/7 mRNA expression level
Table 1
Demographic and clinical characteristics of 409 cases of oral cavity squamous cell carcinoma, stratiﬁed by HPV E6/7 oncogene expression.
Factor N (%) (n = 409) Type-speciﬁc v2 pa
Gold standard HPV
Neg. (%) (n = 385) Pos. (%) (n = 24)
Gender
Female 173 (42.3) 170 (44.2) 3 (12.5)
Male 236 (57.7) 215 (55.8) 21 (87.5) 0.004
Siteb
OSU 130 (31.8) 120 (31.2) 10 (41.7)
PMH 94 (23.0) 90 (23.4) 4 (16.7)
UC 95 (23.2) 90 (23.4) 5 (20.8)
UCSF 90 (22.0) 85 (22.1) 5 (20.8) 0.558
Year of collection
2005–2007 102 (24.9) 98 (25.5) 4 (16.7)
2008–2009 168 (41.1) 155 (40.3) 13 (54.2)
2010–2011 139 (34.0) 132 (34.3) 7 (29.2) 0.694
Anatomic subsite
Alveolar process 39 (9.5) 35 (9.1) 4 (16.7)
Buccal mucosa 34 (8.3) 34 (8.8) 0 (0)
Floor of mouth 83 (20.3) 74 (19.2) 9 (37.5)
Gingiva 31 (7.6) 30 (7.8) 1 (4.2)
Hard palate 25 (6.1) 22 (5.7) 3 (12.5)
Lip 21 (5.1) 20 (5.2) 1 (4.2)
Retromolar trigone 7 (1.7) 7 (1.8) 0 (0)
Tongue 162 (39.6) 156 (40.5) 6 (25.0)
Vestibule of mouth 7 (1.7) 7 (1.8) 0 (0) 0.383
Staging type
Clinical 122 (29.8) 117 (30.4) 5 (20.8)
Pathological 269 (65.8) 252 (65.5) 17 (70.8) 0.481c
Biopsy service 13 (3.2) 13 (3.4) 0 (0)
Missing 5 (1.3) 3 (0.8) 2 (8.3)
AJCC tumor stage
Tis 4 (1.0) 2 (0.5) 2 (8.3)
T1 132 (32.3) 122 (31.7) 10 (41.7)
T2 126 (30.8) 121 (31.4) 5 (20.8)
T3 44 (10.8) 44 (11.4) 0 (0)
T4/a/b/NOS 86 (21.0) 80 (20.8) 6 (25.0) 0.012c
Biopsy service 13 (3.2) 13 (3.4) 0 (0)
Missing 4 (1.0) 3 (0.8) 1 (4.2)
AJCC nodal stage
N0 185 (45.2) 172 (44.7) 13 (54.2)
N1 43 (10.5) 42 (10.9) 1 (4.2)
N2/a/b/c 80 (19.6) 77 (20.0) 3 (12.5)
N3 4 (1.0) 3 (0.8) 1 (4.2)
Nx 81 (19.8) 76 (19.7) 5 (20.8) 0.316c
Biopsy service 13 (3.2) 13 (3.4) 0 (0)
Missing 3 (0.7) 2 (0.5) 1 (4.2)
AJCC metastasis stage
M0 103 (25.2) 99 (25.7) 4 (16.7)
M1 3 (0.7) 3 (0.8) 0 (0)
Mx 266 (65.0) 247 (64.2) 19 (79.2) 0.454c
Biopsy service 13 (3.2) 13 (3.4) 0 (0)
Missing 24 (5.9) 23 (6.0) 1 (4.2)
Tumor differentiation
Grade 1 119 (29.1) 112 (29.1) 7 (29.2)
Grade 2 220 (53.8) 214 (55.6) 6 (25.0)
Grade 3 70 (17.1) 59 (15.3) 11 (45.8) 0.001
Histologic variant
Acantholytic squamous cell carcinoma 21 (5.1) 20 (5.2) 1 (4.2)
Basaloid squamous cell carcinoma 14 (3.4) 5 (1.3) 9 (37.5)
Lymphoepithelial carcinoma (non-nasopharyngeal) 1 (0.2) 1 (0.3) 0 (0)
Papillary squamous cell carcinoma 2 (0.5) 2 (0.5) 0 (0)
Spindle cell squamous carcinoma 3 (0.7) 3 (0.8) 0 (0)
Squamous cell carcinoma, conventional 365 (89.2) 352 (91.4) 13 (54.2)
Verrucous carcinoma 3 (0.7) 2 (0.5) 1 (4.2) <0.001
a Pearson v2 or Fisher’s exact test.
b Dates of collection: 2007–2010, OSU; 2007–2010, PMH; 2005–2011, UC; 2007–2011, UCSF.
c Excluding missing, biopsy service.
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PCR.All p16-positive tumors that were HPV-negative by the above
analysis were further screened for HPV DNA sequences from HPV
4 M.W. Lingen et al. / Oral Oncology 49 (2013) 1–8types other than the high-risk and low-risk types noted above by
consensus primer PCR by use of GP5+/6+ primer sets20 followed
by gel electrophoresis and DNA sequencing.
Statistical considerations
Differences between evaluable and in-evaluable cases as well as
type-speciﬁc gold standard HPV-positive and -negative samples in
demographic and clinical characteristics were analyzed using con-
tingency table chi-square tests or Fisher’s exact test. Nonparamet-
ric Mann–Whitney or Kruskal–Wallis tests were used to determine
equality of medians in age at diagnosis and laboratory testing val-
ues. Contingency tables were used to determine sensitivity, speci-
ﬁcity, and positive and negative predictive values (and 95%
conﬁdence intervals [CI]) for p16 classiﬁcation compared to HR-
HPV E6/7 expression. All reported p values were two-sided. Statis-
tical analyses were performed by use of Stata 10.1 software (Stata-
Corp, College Station, TX).
Results
A ﬂow diagram of the laboratory analysis performed is shown in
Fig. 1. A total of 430 OCSCC were obtained for analysis, and 21
(4.7%) tumors were deemed in-evaluable due to inability to ampli-
fy a control gene (ERV-3) by PCR or absence of detectable expres-
sion of a control gene (RPLPO) by qRT-PCR. The demographic and
clinical characteristics of the 409 cases of OCSCC included in the ﬁ-
nal analysis are shown in Table 1. When evaluable and in-evalu-
able OCSCC were compared with regard to these factors,
evaluable tumors were signiﬁcantly more frequent among men
and were more likely to be tongue cancers (Supplementary Tables
2 and 3).
The total yield and purity of DNA (median 1.95 ugs [interquar-
tile range [IQR], 1.05–5.98], 260/280 ratio 1.63 [IQR 1.56–1.69]) ex-
tracted from parafﬁn-embedded tumors was very good, with a
median yield of 1,068 (IQR 562–1860) human diploid genome
equivalents per microliter of sample (total 50 lL), as estimatedFigure 1 Flow diagram of laboratory analysis of 430 oral cavity squamous cell carcinomas
endogenous retrovirus 3; RPLPO, human ribosomal protein large; IHC, immunohistoch
chain reaction; ISH, in situ hybridization; qRT-PRC, quantitative reverse transcriptase poby real-time PCR for a control gene (ERV-3). The RNA was of sim-
ilarly high quantity and quality (median 2.70 ugs [IQR 1.38–
6.36], 260/280 ratio 1.95 [IQR1.83–2.0]), with a median of 371
(IQR 167–878) RPLPO copies per microliter of sample, as estimated
by qRT-PCR. The distribution of values for ERV3 and RPLPO among
evaluable cases is shown in Fig. 2, stratiﬁed by calendar period of
diagnosis. Although values declined signiﬁcantly with calendar
time, yield among older samples remained sufﬁcient for analysis.
In our analysis, HR-HPV DNA was detected in 40 of 409 (9.8%,
95%CI 6.9–12.7) OCSCC. Neither possibly high-risk (26, 53, 66)
nor low-risk (6, 11, 40, 43, 44, 54, 69, 71, 70, 74) HPV types were
detected in any of the tumors. When evaluated by use of the
Inno-LiPA assay, 31 of 409 OCSCC were negative for the human
DNA control. However, all of these samples had high human DNA
content when evaluated for a control gene (ERV-3) by quantitative
real-time PCR (median 7327, IQR [3343, 12678]), consistent with
the presence of an inhibitor of the Inno-LiPA assay. Therefore, these
31 samples were also evaluated for HPV DNA and mRNA by use of
15 different HR-HPV type-speciﬁc real-time PCR assays, and none
were positive. Forty of 378 evaluable samples were positive in
the Inno-LiPA assay [HPV16 (n = 27), HPV 18 (2), HPV31 (2),
HPV33 (2), HPV35 (1), HPV39 (2), HPV45 (1), HPV51 (2), HPV 52
(1)]. HPV16 DNA and mRNA were not detected in any additional
cases when all 409 tumors were evaluated by real-time PCR and
qRT-PCR.
Of the 40 samples positive for HR-HPV DNA by the Inno-LiPA as-
say, 27 were conﬁrmed positive by type-speciﬁc real-time PCR for
the corresponding HPV type. When evaluated for HR-HPV E6/7
expression, 24 cases (5.9%, 95%CI 3.6–8.2) were positive [HPV16
(n = 15), HPV 18 (2), HPV31 (2), HPV33 (2), HPV35 (1), HPV39
(1), HPV45 (1)]. The laboratory analysis for the 16 OCSCC that were
HPV positive by Inno-LiPA but negative for HPV E6/7 expression
analysis is summarized in Supplementary Table 4. Of note, the
HPV viral load among cases that were positive for HPV DNA but
negative for E6/7 expression was signiﬁcantly lower than for cases
positive for E6/7 expression (0 [IQR 0.0–0.002] versus 9.8 [IQR 2.2–
152.0] copies per cell, p < 0.001). The speciﬁcity of HPV DNA to tu-. See text for detailed methods. Abbreviations: SCC, squamous cell carcinoma; ERV3,
emistry; HR-HPV, high-risk human papillomavirus; RT-PCR, real-time polymerase
lymerase chain reaction; WS, wide spectrum.
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Figure 2 The distribution of values for controls for PCR ampliﬁcation of human DNA (ERV-3) and human mRNA reverse transcribed to cDNA (RPLPO) observed in the 409 oral
cavity squamous cell carcinomas scored as evaluable, stratiﬁed by year of specimen collection. (A) The number of human diploid genome equivalents (e.g. cell number) per
sample that were evaluated for the presence of HPV DNA by means of Inno-LiPA PCR analysis are shown as estimated by quantitative real-time PCR for a single copy human
gene, ERV-3. (B) The number of transcripts for a control gene (RPLPO) per sample, corresponding to that evaluated for the presence of HPV E6/7 mRNA transcripts by qRT-PCR,
is shown as estimated by qRT-PCR. The box plot to the right of the scatter plot indicates the median and the 25th and 75th percentiles; whiskers extend to the 5th and 95th
percentiles. Kruskal–Wallis test for equality of medians, p = 0.0001 for both factors.
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of 24 cases positive for HR-HPV E6/7 expression. Representative
cases are shown in Fig. 3.
The characteristics of HR-HPV E6/7 expression positive and neg-
ative oral cavity cases are compared in Table 1. Median age of HPV-
positive cases was similar to HPV negative cases (61 versus
64 years, p = 0.35). A majority of HPV-positive cases were ﬂoor of
mouth or tongue cancers, but the anatomic-site distribution did
not differ from HPV-negative cases. HPV-positive cases were signif-
icantly more likely than HPV-negative cases to be diagnosed
among men, to be of early tumor stage, to be poorly differentiated
and to have basaloid histopathology (Table 1).
When tumors were evaluated for p16 expression, 46 (11.2%,
95%CI 8.2–14.3) of 409 were positive by H score criteria, including
19 of 24 HR-HPV E6/7 positive tumors and 27 of 385 negative tu-
mors. The sensitivity of p16 for HR-HPV E6/7 expression was 79.2%
(95%CI 57.9–92.9), speciﬁcity 93.0% (95%CI 90.0–95.3), positive-
predictive value 41.3% (95%CI 27.0–56.8) and negative-predictive
value 98.6% (95%CI 96.8–99.6). When evaluated for the presence
of additional HPV types by use of GP5+/6+ consensus primer PCR,
no HPV DNA sequences were detected in the 27 p16-positive/
HPV-negative cases.
A summary of the clinical characteristics and HPV testing re-
sults for all 24 OCSCC positive for HR-HPV E6/7 expression is
shown in Table 2.Discussion
The incidence of HPV-positive oropharynx cancer increased by
225% from 1988 to 2004 in the United States, in contrast to a
50% decline in incidence of HPV-negative cancers.7 Presumably,
the population-level changes over calendar time in tobacco smok-
ing and sexual behaviors that are hypothesized to underlie this eti-
ologic shift would similarly affect OCSCC. Given the consistently
high estimates (P70%) of the HPV-etiologic fraction in oropharyn-
geal cancers diagnosed in North America after 20007,15,21, we spe-
ciﬁcally chose to investigate the etiologic fraction for HPV among a
series of contemporaneously diagnosed cases of OCSCC from North
America. To our knowledge, this is the largest and most compre-
hensive analysis of HR-HPV E6/7 expression speciﬁc to oral cavitycancers. We observed HR-HPV E6/7 expression in approximately
6% of OSCC. Analogous to oropharynx cancers, HPV-positive can-
cers were signiﬁcantly associated with male gender, early tumor
stage, and poorly differentiated, basaloid histopathology.
In contrast to the anatomic site speciﬁcity for the lingual and
palatine tonsils in the oropharynx, HPV-positive and negative
OCSCC had a similar anatomic site distribution. In this study, the
small tumor size and the anatomic discontinuity of the HPV-posi-
tive OCSCC from the oropharynx indicate they are unlikely to rep-
resent misclassiﬁed oropharynx cancers. The oral region therefore
appears analogous to the genital tract with regard to ﬁeld effects of
HPV infection, wherein the overwhelming majority of cancers arise
from distinct anatomic sites with apparent increased susceptibility
to HPV infection and/or transformation (e.g. the tonsil crypt and
cervical transformation zone), with a minority sporadically arising
from other anatomic sites (e.g. the oral cavity and the vagina,
vulva).
Several recently published studies have identiﬁed a high pro-
portion (35–55%) of OCSCC with detectable HPV DNA by sensitive
PCR methods.22,23 Our data indicate that caution should be used in
inferring HPV-causality based on DNA detection alone, as approx-
imately half of HPV DNA-positive cases were conﬁrmed as positive
for HR-HPV E6/7 expression. Additionally, the HPV viral load was
markedly lower among HR-HPV-E6/7 expression-negative tumors,
possibly consistent with the presence of a pathophysiologically
unrelated oral HPV infection. In a recent population-based study
in the US, gender, age and intensity of current tobacco smoking
were strongly associated with prevalent oral HPV infection.24 In
that study, oral HPV infection was detected in 10% of men,
11% of individuals aged 55–64 years and among 20% of current
smokers of one or more packs per day. Given the gender and age
distribution of our study population, approximately 10–20% would
be expected to have an oral HPV infection. In a recent meta-analy-
sis of case-control studies, oral HPV infection was associated with a
fourfold increase in odds of oral cavity carcinoma (OR 3.98, 95%CI
2.62–6.02).25 However, the authors noted that their analysis did
not account for the possible effects of tobacco smoking. Therefore,
there is considerable potential for residual confounding of the
association between oral HPV infection and OCSCC by tobacco
smoking. Nevertheless, relatively strong associations have been
observed between high-risk oral HPV infections overall and OCSCC
(A) (B) (C) 
(D) (E) (F) 
(G) (H) (I) 
(J) (K) (L) 
Figure 3 Representative histopathology for oral cavity squamous cell carcinomas that were positive for HR-HPV E6/7 expression. Cases evaluated by hematoxylin and eosin
staining (A, D, G, J), for expression of p16 by IHC (B, E, H, K), and for HPV presence by ISH (C, F, I, L). Panel A–C is an example of a poorly differentiated, basaloid squamous cell
carcinoma of the alveolar process that was p16-positive (B) and HPV16 ISH-positive (C). The tumor was positive for HPV16 E6/7 expression. Note the hyperchromatic cells
with scant cytoplasm, marked nuclear atypia, and high mitotic activity characteristic of basaloid carcinoma. Panel D–F is an example of a well differentiated squamous cell
carcinoma in situ of the ﬂoor of mouth that was p16-positive (E) and HPV31 ISH-positive (F). The tumor was positive for HPV31 E6/7 expression. Panel G-I is an example of a
well differentiated squamous cell carcinoma of the hard palate that was p16-positive (H) and HPV16 ISH-negative (I). The tumor was negative for HPV DNA and mRNA. Panel
J–L is an example of a poorly differentiated, basaloid squamous cell carcinoma of the ﬂoor of mouth that was p16-negative (K) and HPV16 ISH-positive (L). The tumor was
positive for HPV16 E6/7 expression.
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in contrast to weak associations observed for serologic measures of
HPV16 exposure.28–32 The HPV type distribution we observed in
our series among OCSCC was signiﬁcantly more diverse than for
the corresponding series of oropharyngeal cancers (94.9% HPV16,
5.1% non-16),15 with approximately 38% of positive cases attribut-able to HR-HPV types other than 16. Studies that focus exclusively
on HPV16 may therefore underestimate associations.
p16 IHC is an accepted surrogate diagnostic biomarker for HPV
status for OPSCC, and in our recent analysis had a positive predic-
tive value of 93% for HR-HPV E6/7 expression.15 However, the po-
sitive-predictive value of p16 for HPV in OCSCC is very poor
Table 2
Clinical and pathologic characteristics of 24 oral cavity squamous cell carcinomas with HPV E6/7 expression.
Sample Anatomic
subsite
Histologic
variant
Tumor
differentiation
Staging
type
Tumor
stage
Nodal
stage
HPV
type
Viral copies per
single ERV3 (adj)
E6/7 mRNA copies
per 1000 RPLP0
p16 IHC
status
HPV ISH
status
1 Alveolar
process
SCC,
conventional
Well Clinical T1 N0 16 0.9 127.3 Pos Pos
2 Floor of
mouth
Basaloid SCC Poor Pathological T2 N0 16 8.4 94.6 Neg Pos
3 Floor of
mouth
Basaloid SCC Poor Pathological T1 N0 16 3.9 10.5 Pos Pos
4 Tongue SCC,
conventional
Moderate Pathological T4a N2b 16 153.7 144.5 Pos Pos
5 Alveolar
process
Basaloid SCC Poor Pathological T2 N2c 16 11.2 509.0 Pos Pos
6 Tongue Verrucous
carcinoma
Well Pathological T1 N0 31 6.2 1121.5 Pos Pos
7 Floor of
mouth
SCC,
conventional
Well – Tis Nx 18 7205.4 686.2 Pos Pos
8 Gingiva Basaloid SCC Poor Pathological T4a N0 35 573.6 5179.0 Neg Neg
9 Tongue SCC,
conventional
Moderate Pathological T2 N0 18 3.3 170.7 Pos Pos
10 Hard
palate
SCC,
conventional
Poor Clinical T1 N0 16 162.0 11.7 Neg Pos
11 Floor of
mouth
Basaloid SCC Poor Clinical Tis Nx 16 0.1 3.1 Neg Pos
12 Tongue SCC,
conventional
Moderate Pathological T1 N0 31 28.3 583.1 Pos Neg
13 Tongue SCC,
conventional
Well Pathological T1 N0 33 0.1 32.2 Pos Pos
14 Floor of
mouth
Acantholytic
SCC
Poor Pathological T2 N1 16 0.02 37.5 Neg Neg
15 Hard
palate
SCC,
conventional
Moderate Clinical T2 Nx 16 43.6 5.2 Pos Pos
16 Alveolar
process
Basaloid SCC Poor Pathological T1 N0 16 85.9 536.3 Pos Pos
17 Tongue SCC,
conventional
Moderate Pathological T1 Nx 16 2.0 168.6 Pos Pos
18 Alveolar
process
SCC,
conventional
Well Pathological T1 N0 33 149.9 536.4 Pos Pos
19 Floor of
mouth
SCC,
conventional
Moderate – – – 16 2.5 456.5 Pos Pos
20 Floor of
mouth
SCC,
conventional
Well Clinical T1 N0 16 286.5 122.1 Pos Pos
21 Hard
palate
Basaloid SCC Poor Pathological T4a Nx 45 0.8 544.4 Pos Neg
22 Floor of
mouth
Basaloid SCC Poor Pathological T4a N2b 16 46.2 138.0 Pos Pos
23 Floor of
mouth
Basaloid SCC Poor Pathological T4b N3 16 6.7 1565045.0 Pos Pos
24 Lip SCC,
conventional
Well Pathological T4a N0 39 309.2 3373.1 Pos Pos
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for HR-HPV E6/7 expression. Given the lower overall prevalence
of HPV in OCSCC relative to OPSCC, this is not unexpected.
Although constituting a low percentage of OCSCC overall, the
p16-positive HPV-negative proportion (7.0%) exceeded that for
HR-HPV E6/7 expression-positive OCSCC. Our data therefore indi-
cate that p16 IHC should not be used as a surrogate for HPV testing
in OCSCC. Whether or not p16 expression is predictive of tumor
HPV status in tumors arising from other anatomic sites such as
the larynx will need to be evaluated.
Our study has several potential limitations. Although our esti-
mate of the HPV-etiologic fraction was precise, it may not reﬂect
the population-level HPV-attributable fraction in North America.
Our study was not population based. We note, however, that the
HPV-etiologic fraction of 68% for oropharynx cancers in our series
of patients diagnosed after 200015 was quite similar to the 72% we
previously observed in a US population-based analysis with identi-
cal laboratory methods.7 A US population based analysis of HPV in
OCSCC currently being conducted by the US Centers for Disease
Control and Prevention will address this issue. DNA and RNA deg-
radation in parafﬁn may decrease sensitivity of HPV detection, butwould result in an underestimate of the etiologic fraction. Addi-
tionally, our PCR assays are all speciﬁcally designed to yield small
amplicons, as appropriate for degraded DNA. Although we ob-
served a signiﬁcant decline in DNA and RNA yield with increasing
time since diagnosis, the quality and quantity remained far above
that necessary for the specimen to be evaluable.
It is now clear that HPV-positive OPSCC constitutes a unique
epidemiological and clinical entity. Risk factor proﬁles17 and prog-
nosis21 are different for HPV-positive and HPV-negative OPSCC.
Due to absence of relevant data, we could not investigate associa-
tions between HPV status and cofactors (e.g. tobacco and alcohol
use) or survival outcomes for OCSCC, and therefore this will require
further study. Of particular interest will be the association of HPV
and p16 status in combination with survival of OCSCC and whether
or not the small subset of HR-HPV E6/7 positive OCSCC could be
treated with organ preservation therapy in lieu of surgical
resection.
Despite these limitations, our data may have important implica-
tions for the primary prevention of oral cavity carcinoma. The
International Agency for Research on Cancer (IARC) recently esti-
mated the HPV-attributable fraction for OPSCC to be 26% world-
8 M.W. Lingen et al. / Oral Oncology 49 (2013) 1–8wide, accounting for approximately 22,500 incident cases of OPSCC
each year.33 If as high as 5% of the 263,000 annual cases of OCSCC34
are also due to HPV infection, a total of 35,650 oral cancer cases
worldwide might be preventable through HPV vaccination (assum-
ing efﬁcacy equivalent to that for genital infection). In the US for
2012, the corresponding number would be 10,500 cases.7 The
broader HPV type distribution for OCSCC than OPSCC might also
have implications for potential beneﬁts from newer generation
HPV vaccines that may protect against a broader range of HPV
types.
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